John Vavricka

CIK: 0001829630

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)2 (33.3%)

Derivative conversions

Awards (A)2 (33.3%)

Compensation grants

Other (G, F, J, C, D, …)2 (33.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

AVIR

Atea Pharmaceuticals, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (6 total)

AVIR
Atea Pharmaceuticals, Inc.
Jan 31, 2026
Exercise(M)
Direct
42.1K shares-
AVIR
Atea Pharmaceuticals, Inc.
Jan 31, 2026
Tax Payment(F)
Direct
11.6K shares at avg. $4.24$49K
AVIR
Atea Pharmaceuticals, Inc.
Jan 31, 2026
Award(A)
Stock Option (Right to Buy)
Direct
119.5K shares-
AVIR
Atea Pharmaceuticals, Inc.
Jan 31, 2025
Exercise(M)
Direct
33.3K shares-
AVIR
Atea Pharmaceuticals, Inc.
Jan 31, 2025
Award(A)
Direct
8.8K shares-
AVIR
Atea Pharmaceuticals, Inc.
Jan 31, 2025
Tax Payment(F)
Direct
11.5K shares at avg. $3.06$35K

		Type	Shares	Price		Ownership
Jan 31, 2026	AVIR Atea Pharmaceuticals, Inc.	Exercise(M)	42,083	-	$0	Direct
Jan 31, 2026	AVIR Atea Pharmaceuticals, Inc.	Tax Payment(F)	11,570	$4.24	$49,057	Direct
Jan 31, 2026	AVIR Atea Pharmaceuticals, Inc.	Award(A) Stock Option (Right to Buy)	119,520	-	-	Direct
Jan 31, 2025	AVIR Atea Pharmaceuticals, Inc.	Exercise(M)	33,333	-	-	Direct
Jan 31, 2025	AVIR Atea Pharmaceuticals, Inc.	Award(A)	8,750	-	-	Direct
Jan 31, 2025	AVIR Atea Pharmaceuticals, Inc.	Tax Payment(F)	11,517	$3.06	$35,242	Direct

1-6 of 6 transactions

About Vavricka John

Vavricka John (SEC CIK 0001829630) files insider reports with the SEC as Chief Commercial Officer of Atea Pharmaceuticals, Inc. (AVIR).

Signal8 holds 2 ownership filings by Vavricka John, all Form 4s, filed between Feb 4, 2025 and Feb 3, 2026. Those filings report 6 transactions, from Jan 31, 2025 to Jan 31, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Vavricka John's filings is in BOSTON, MA.

Recent filings by Vavricka John

Jan 31, 2026: Option exercise of AVIR shares (Form 4, code M).
Jan 31, 2026: Tax withholding of AVIR shares (Form 4, code F).
Jan 31, 2026: Grant or award of AVIR derivative securities (Form 4, code A).
Jan 31, 2025: Option exercise of AVIR shares (Form 4, code M).
Jan 31, 2025: Grant or award of AVIR shares (Form 4, code A).

Other insiders filing for Atea Pharmaceuticals, Inc. (AVIR)

Lucidi Bruno, Director
BERGER FRANKLIN M, Director
Berman Howard, Director
DUNCAN BARBARA GAYLE, Director
Polsky Bruce, Director
Murphy Polly A., Director

How to read Form 4 transaction codes